About this trial
Patient Profile
Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma
Where’s this trial being run?
Bon Secours Cork and St Vincents University Hospital
Can I join this study / trial?
The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.
Why not Print this page and bring it with you. It will help your doctor and research team advise you.
Print this pageFor more detailed information
Click HereQuestions?
Here’s a list of questions you may have for your doctor or local cancer research team.
QuestionsSummary Data
| Name: | Astellas 8951-CL-5201 |
|---|---|
| Number: | CTRIAL-IE 18-44 |
| Full Title: | A Phase 2, Open-Label, Randomized Study to Assess the Antitumor Activity and Safety of Zolbetuximab (IMAB362) in Combination with Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects with Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma |
| Principal Investigator: | Ray McDermott |
|---|---|
| Type: | Industry Sponsored |
| Sponsor: | Astellas |
| Recruitment Started: |
Global: Ireland: |
| Global Recruitment Target: | 369 |
|---|---|
| Ireland Recruitment Target: | 3 |